Genetics of Cystic Fibrosis Clinical Implications

被引：32

作者：

Egan, Marie E. ^{[1
]}

机构：

[1] Yale Univ, Dept Pediat, Sch Med, 333 Cedar St,Fitkin 526, New Haven, CT 06520 USA

来源：

CLINICS IN CHEST MEDICINE | 2016年 / 37卷 / 01期

关键词：

Cystic fibrosis transmembrane conductance regulator protein mutation; Potentiator; Corrector; Read through agent; Genetic modifier; DOUBLE-BLIND; IVACAFTOR TREATMENT; CFTR POTENTIATOR; MUTATION; F508DEL-CFTR; EFFICACY; SAFETY; LUMACAFTOR; EXPRESSION; SEQUENCES;

D O I：

10.1016/j.ccm.2015.11.002

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Cystic fibrosis (CF) is a common life-shortening autosomal recessive genetic disorder caused by mutations in the gene that encodes for the cystic fibrosis transmembrane conductance regulator protein (CFTR). Almost 2000 variants in the CFTR gene have been identified. The mutational classes are based on the functional consequences on CFTR. New therapies are being developed to target mutant CFTR and restore CFTR function. Understanding specific CF genotypes is essential for providing state-of-the art care to patients. In addition to the variation in CFTR genotype, there are several modifier genes that contribute to the respiratory phenotype.

引用

页码：9 / +

页数：9

共 34 条

[11] Efficacy and Safety of Ivacaftor in Patients Aged 6 to 11 Years with Cystic Fibrosis with a G551D Mutation [J].

Davies, Jane C. ;

Wainwright, Claire E. ;

Canny, Gerard J. ;

Chilvers, Mark A. ;

Howenstine, Michelle S. ;

Munck, Anne ;

Mainz, Jochen G. ;

Rodriguez, Sally ;

Li, Haihong ;

Yen, Karl ;

Ordonez, Claudia L. ;

Ahrens, Richard .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187 (11) :1219-1225

[12] Another Beginning for Cystic Fibrosis Therapy [J].

Davis, Pamela B. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (03) :274-276

[13] Revertants, Low Temperature, and Correctors Reveal the Mechanism of F508del-CFTR Rescue by VX-809 and Suggest Multiple Agents for Full Correction [J].

Farinha, Carlos M. ;

King-Underwood, John ;

Sousa, Marisa ;

Correia, Ana Raquel ;

Henriques, Barbara J. ;

Roxo-Rosa, Monica ;

Da Paula, Ana Carina ;

Williams, Jonathan ;

Hirst, Simon ;

Gomes, Claudio M. ;

Amaral, Margarida D. .

CHEMISTRY & BIOLOGY, 2013, 20 (07) :943-955

[14] Ivacaftor in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation [J].

Flume, Patrick A. ;

Liou, Theodore G. ;

Borowitz, Drucy S. ;

Li, Haihong ;

Yen, Karl ;

Ordonez, Claudia L. ;

Geller, David E. .

CHEST, 2012, 142 (03) :718-724

[15] Managing the Underlying Cause of Cystic Fibrosis: A Future Role for Potentiators and Correctors [J].

Galietta, Luis J. V. .

PEDIATRIC DRUGS, 2013, 15 (05) :393-402

[16] Targeted replacement of normal and mutant CFTR sequences in human airway epithelial cells using DNA fragments [J].

Goncz, KK ;

Kunzelmann, K ;

Xu, ZD ;

Gruenert, DC .

HUMAN MOLECULAR GENETICS, 1998, 7 (12) :1913-1919

[17] Expression of ΔF508 CFTR in normal mouse lung after site-specific modification of CFTR sequences by SFHR [J].

Goncz, KK ;

Colosimo, A ;

Dallapiccola, B ;

Gagné, L ;

Hong, K ;

Novelli, G ;

Papahadjopoulos, D ;

Sawa, T ;

Schreier, H ;

Wiener-Kronish, J ;

Xu, Z ;

Gruenert, DC .

GENE THERAPY, 2001, 8 (12) :961-965

[18] Cystic Fibrosis Gene Therapy in the UK and Elsewhere [J].

Griesenbach, Uta ;

Pytel, Kamila M. ;

Alton, Eric W. F. W. .

HUMAN GENE THERAPY, 2015, 26 (05) :266-275

[19] Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial [J].

Kerem, Elton ;

Konstan, Michael W. ;

De Boeck, Kris ;

Accurso, Frank J. ;

Sermet-Gaudelus, Isabelle ;

Wilschanski, Michael ;

Elborn, J. Stuart ;

Melotti, Paola ;

Bronsveld, Inez ;

Fajac, Isabelle ;

Malfroot, Anne ;

Rosenbluth, Daniel B. ;

Walker, Patricia A. ;

McColley, Susanna A. ;

Knoop, Christiane ;

Quattrucci, Serena ;

Rietschel, Ernst ;

Zeitlin, Pamela L. ;

Barth, Jay ;

Elfring, Guy L. ;

Welch, Ellen M. ;

Branstrom, Arthur ;

Spiegel, Robert J. ;

Peltz, Stuart W. ;

Ajayi, Temitayo ;

Rowe, Steven M. .

LANCET RESPIRATORY MEDICINE, 2014, 2 (07) :539-547

[20] Chronic ivacaftor treatment: Getting F508del-CFTR into more trouble? [J].

Mall, Marcus A. ;

Sheppard, David N. .

JOURNAL OF CYSTIC FIBROSIS, 2014, 13 (06) :605-607

← 1 2 3 4 →